Amarin terminates development of Miraxion for Huntington's
04 December 2009
Asher Mullard
Please Login to read the full article.
04 December 2009
Asher Mullard
asher.mullard@informa.com
Amarin has withdrawn an EU filing of its lead drug candidate, Miraxion (AMR101; ethyl eicosapentaenoic acid), for Huntington's disease. The European Medicines Agency said that further clinical studies would be needed to establish the drug's efficacy in Huntington's, and Amarin has decided that it...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Omthera seeks 'best in class' status for prescription omega-3 product Epanova
- Amarin gains 'rare' 3rd SPA with US FDA for fish oil pill CV study
- Omthera raises $34 million to take omega-3 fatty acid drug into Phase III
- US Capitol Capsule: Zombies, doomsday and debt ceilings, oh my
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
